Home example 2 - Pharmamarketeer

onderzoek

Rapastinel Fails to Meet Primary Endpoint in Phase 3 Adjunctive MDD Trials

Clinical studies evaluating the safety, efficacy and tolerability of rapastinel as an adjunctive treatment for major depressive disorder (MDD) did not meet primary and key secondary endpoints, according to topline...

Monthly Prescribing Reference (MPR): Drugs in the Pipeline

3 x gelezen

technologie onderzoek

UK Institute to harness disruptive technology to transform drug discovery

Business Secretary Greg Clark today announced funding for a series of ambitious technology projects that will transform the way medicines are discovered, enabling the pharmaceutical industry to develop groundbreaking...

Drug Discovery Today

3 x gelezen

marketing

Hoe kun je klanten de coronaregels beter laten volgen? 9 psychologische manieren

Coronaregels ‘Flatten the curve’, dat is het belangrijkste nu. Toch lijkt niet iedereen zich aan de (verscherpte) regels van de overheid te houden. Hoe kunnen we de bestaande communicatie dan nóg beter maken? Hoe kunnen...

Frankwatching.nl

3 x gelezen

wet- en regelgeving

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

COVID-19 antibody cocktail
Drug approved to treat high-risk patients with mild to moderate COVID-19.

PMLiVE

3 x gelezen

marketing

AI-modellen worden meer ingezet en steeds geavanceerder

Binnen de data-driven marketingsector worden modellen steeds geavanceerder. Dat blijkt uit de DDMA AI Maturity Test 2022. Van de organisaties die AI inzetten geeft maar liefst 92% van de participanten aan meer gebruik...

fonkonline.nl

3 x gelezen

overig

5 brands share their content marketing process

It’s a hazard of the job for content marketers. When you read or see a piece of high-quality content, you wonder how it got created. You ask yourself, “What does this company do to create great content? Is it great for...

contentmarketinginstitute.com

3 x gelezen

wet- en regelgeving

FDA approves Pfizer’s drug for advanced breast cancer

The U.S. Food and Drug Administration said on Tuesday it approved Pfizer Inc’s drug for an advanced form of breast cancer tied to an inherited gene mutation.

Reuters Health

3 x gelezen

farma-industrie

Pfizer and Novartis partner up to develop combo therapies for NASH

Pfizer and Novartis are set to team up in a non-exclusive partnership aimed at the clinical development of one or more combo therapies for the treatment of non-alcoholic steatohepatitis (NASH). Under the partnership...

InPharm.com

3 x gelezen

wet- en regelgeving

Keytruda Gets FDA Approval for Hepatocellular Carcinoma

The approval was based on data from the KEYNOTE-224 study, a single-arm trial in patients with HCC who had disease progression on or after sorafenib or were intolerant to sorafenib; had measurable disease; and Child...

Monthly Prescribing Reference (MPR): Drug News

3 x gelezen

onderzoek

Phase 3 failure of asthma therapy sends Vectura’s ailing shares falling

Vectura has announced it is terminating development of its severe asthma therapy VR475, an inhaled formulation of the corticosteroid budesonide, after it failed in Phase 3 trials to demonstrate a significant impact on...

InPharm.com

3 x gelezen

Latest articles

Rapastinel Fails to Meet Primary Endpoint in Phase 3 Adjunctive MDD Trials

UK Institute to harness disruptive technology to transform drug discovery

Hoe kun je klanten de coronaregels beter laten volgen? 9 psychologische manieren

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

AI-modellen worden meer ingezet en steeds geavanceerder

5 brands share their content marketing process

FDA approves Pfizer’s drug for advanced breast cancer

Pfizer and Novartis partner up to develop combo therapies for NASH

Keytruda Gets FDA Approval for Hepatocellular Carcinoma

Phase 3 failure of asthma therapy sends Vectura’s ailing shares falling

Wekelijkse highlights per e-mail

Algemene informatie